Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Blinded, Randomized Controlled Trial Assessing the Diagnostic Yield and Tissue Adequacy of 22G Adapt Versus 22G Franseen Fine-Needle Biopsy for Solid Lesions Under Endoscopic Ultrasound Guidance

NCT07012694 is registered in ClinicalTrials.gov with Huazhong University of Science and Technology as lead sponsor.

NCT NCT07012694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07012694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Blinded, Randomized Controlled Trial Assessing the Diagnostic Yield and Tissue Adequacy of 22G Adapt Versus 22G Franseen Fine-Needle Biopsy for Solid Lesions Under Endoscopic Ultrasound Guidance
Lead sponsor
Huazhong University of Science and Technology
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
December 10, 2026
Enrollment
576 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abdominal neoplasm, excluding pancreas neoplasm, mediastinal neoplasms, pancreatic neoplasms